In the light of ongoing clinical cancer trials that are utilizing systemically administered CD73 modifiers such as inhibitors or blocking antibodies (Supporting Information Table S1) to boost the immune system, it therefore becomes imperative to decipher this function and prevent potential deleterious effects that could be caused by a systemic reduction of CD73 activity in the lymphatic vasculature. The gene discussed is NT5E; the disease is cancer.